PCSK9 and atherosclerosis: These findings support the concept that, in addition to its well-established action on LDLR modulation in hepatocytes, PCSK9 can also exert direct effects on atherogenesis in the absence of systemic lipid changes, engaging with other receptors or proteins involved in atherosclerosis pathogenesis [92,93].